secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001232524-24-000031
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma Q1 GAAP net loss $14.6M, non-GAAP EPS $2.68; affirms FY24 revenue guidance $4.0-4.2B
--------------------------------------------------------------------------------

- Total revenues $902M (+1% YoY); GAAP net loss $14.6M ($0.23 loss/diluted) vs net income $69.4M ($1.04/diluted) in 1Q23.
- Non-GAAP adjusted net income $182.2M ($2.68 EPS) down from $285.3M ($3.95 EPS); cost increases in SG&A and R&D.
- Key growth drivers: Xywav +14%, Epidiolex +5%, Rylaze +20% YoY; Xyrem fell 64% to $64.2M.
- Oncology revenues +13% to $257.5M; zanidatamab BLA for 2L BTC submitted; Phase 2b suvecaltamide data expected late 1H24.
- FY24 guidance affirmed: total revenue $4.0-4.2B, non-GAAP gross margin ~93%, non-GAAP EPS $18.15-19.35.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252424000031/0001232524-24-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252424000031/jazz-20240501.htm
  HTML page:      https://secwatch.observer/filing/0001232524-24-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer